New therapeutic strategies for high-risk acute myeloid leukemia Journal Article
| Authors: | Menghrajani, K.; Tallman, M. S. |
| Article Title: | New therapeutic strategies for high-risk acute myeloid leukemia |
| Abstract: | Purpose of review Treatments for acute myeloid leukemia (AML) had remained essentially unchanged for several years; however, the advent of molecular testing has generated insight into the biology of this disease which is now being translated into clinical practice. New treatment strategies which improve drug delivery and exploit cellular targets are changing the landscape of how we treat this disease. Recent findings Induction therapy is in the process of changing for several patient populations. The introduction of CPX-351 offers a novel strategy for treating patients with therapy-related AML or AML with myelodysplasia-related changes; gemtuzumab ozogamicin may become incorporated into standard induction therapy, especially for patients with core-binding factor leukemias; and for older adults, combination therapy with venetoclax may offer a more efficacious strategy than the single-agent regimens previously used. Additionally, targeted therapies are now becoming available for patients with mutations in FMS-like tyrosine kinase 3 (FLT3) or isocitrate dehydrogenase 2 (IDH2), ushering in an era of personalized medicine in the treatment of AML. Summary The US Food and Drug Administration approval of several agents in 2017 will change the way AML treatment is approached and will offer both clinicians and patients a new armamentarium with which to treat this disease. © 2018 Wolters Kluwer Health, Inc. All rights reserved. |
| Keywords: | cancer chemotherapy; gene mutation; review; cancer combination chemotherapy; drug efficacy; drug targeting; novel therapies; high risk patient; geriatric patient; induction chemotherapy; mutant; gemtuzumab ozogamicin; randomized controlled trial (topic); molecularly targeted therapy; phase 2 clinical trial (topic); meta analysis (topic); phase 3 clinical trial (topic); cd135 antigen; phase 1 clinical trial (topic); midostaurin; acute myeloid leukemia; idh2; antileukemic agent; flt3; new drug; isocitrate dehydrogenase 2; human; priority journal; venetoclax; cytarabine plus daunorubicin; enasidenib; secondary acute myeloid leukemia; cpx-351; relapsed refractory acute myeloid leukemia |
| Journal Title: | Current Opinion in Hematology |
| Volume: | 25 |
| Issue: | 2 |
| ISSN: | 1065-6251 |
| Publisher: | Lippincott Williams & Wilkins, Ltd. |
| Date Published: | 2018-03-01 |
| Start Page: | 90 |
| End Page: | 94 |
| Language: | English |
| DOI: | 10.1097/moh.0000000000000409 |
| PROVIDER: | scopus |
| PUBMED: | 29283906 |
| DOI/URL: | |
| Notes: | Review -- Export Date: 2 April 2018 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
-
649Tallman -
43Menghrajani
Related MSK Work